S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:CMPX

Compass Therapeutics (CMPX) Stock Price, News & Analysis

$2.05
+0.07 (+3.54%)
(As of 03/27/2024 ET)
Today's Range
$1.95
$2.05
50-Day Range
$1.20
$2.29
52-Week Range
$1.15
$3.62
Volume
145,865 shs
Average Volume
334,403 shs
Market Capitalization
$282.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Compass Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
339.0% Upside
$9.00 Price Target
Short Interest
Healthy
2.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of Compass Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.44) to ($0.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.69 out of 5 stars

Medical Sector

458th out of 939 stocks

Biological Products, Except Diagnostic Industry

69th out of 154 stocks

CMPX stock logo

About Compass Therapeutics Stock (NASDAQ:CMPX)

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

CMPX Stock Price History

CMPX Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Compass Therapeutics Inc Ordinary Shares
Compass Therapeutics Provides Corporate Update
Compass Therapeutics Insider Ups Holding During Year
TD Cowen Keeps Their Buy Rating on COMPASS Pathways (CMPS)
Compass Therapeutics GAAP EPS of -$0.09
See More Headlines
Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CMPX
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$10.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+339.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.17 per share

Miscellaneous

Free Float
96,312,000
Market Cap
$282.06 million
Optionable
Not Optionable
Beta
0.76
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Vered Bisker-Leib M.D. (Age 52)
    MBA, Ph.D., Chief Executive Officer
    Comp: $806.43k
  • Dr. Thomas J. Schuetz M.D. (Age 63)
    Ph.D., Co-Founder, President of Research & Development and Vice Chair
    Comp: $829.56k
  • Mr. Neil L. Lerner CPA (Age 57)
    Vice President of Finance
  • Mr. Jonathan Anderman J.D.
    VP, Head of Legal & Corporate Secretary
  • Anna Gifford
    Communications Manager
  • Dr. Minori Rosales M.D. (Age 61)
    Ph.D., Senior VP & Head of Clinical Development
  • Ms. Karin Herrera B.A.
    VP & Head of Clinical Operations
  • Dr. James Kranz Ph.D.
    VP and Head of Chemistry Manufacturing & Controls

CMPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Compass Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMPX shares.
View CMPX analyst ratings
or view top-rated stocks.

What is Compass Therapeutics' stock price target for 2024?

2 brokers have issued 12 month target prices for Compass Therapeutics' stock. Their CMPX share price targets range from $8.00 to $10.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 339.0% from the stock's current price.
View analysts price targets for CMPX
or view top-rated stocks among Wall Street analysts.

How have CMPX shares performed in 2024?

Compass Therapeutics' stock was trading at $1.56 at the start of the year. Since then, CMPX shares have increased by 31.4% and is now trading at $2.05.
View the best growth stocks for 2024 here
.

When is Compass Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CMPX earnings forecast
.

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) posted its earnings results on Thursday, November, 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02.

When did Compass Therapeutics IPO?

Compass Therapeutics (CMPX) raised $50 million in an initial public offering on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager.

Who are Compass Therapeutics' major shareholders?

Compass Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.20%), Vanguard Group Inc. (3.20%), Blue Owl Capital Holdings LP (2.22%), Northern Trust Corp (0.60%), Monashee Investment Management LLC (0.39%) and Braidwell LP (0.25%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib.
View institutional ownership trends
.

How do I buy shares of Compass Therapeutics?

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMPX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners